Lilly claims the weight-loss drug reduced the risk of heart failure by 38 per cent in trials
Trial results show that Eli Lilly’s weight-loss drug Zepbound reduces the risk of hospitalisation, death and other outcomes for adults with obesity and a common type of heart failure, the company said on Thursday, continuing to gather evidence of the drug’s broader health benefits.
POPULAR POSTS
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
Mission: Impossible 8 title revealed
November 13, 2024
LIVE STREAM